Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperprolactinaemia: a multi-country, nested case-control study

Feb-12

Cardiovascular Neurology Pharmacoepidemiology

AUTHORS : Gianluca Trifirò, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 1, Consolare Valeria Street, 98125, Messina, Italy AND Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands – Email: trifirog@unime.it – Profile: https://www.unime.it/it/persona/gianluca-trifir%C3%B2

JOURNAL : Drug Safety

REFERENCE: 35(2):159-71

DOI : 10.2165/11594940-000000000-00000

Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperprolactinaemia: a multi-country, nested case-control study

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement